Reports from the 2017 PDA/FDA Joint Regulatory Conference
Guy Villax explains shifting trends in pharma
Pharma companies are constantly challenged to produce innovative products while also ensuring product quality.
The 2017 PDA/FDA Joint Regulatory Conference in Washington, D.C., focused exactly on that: How can industry and the U.S. FDA adapt current quality standards to innovative therapies? As not everyone could attend the Sept. 11-13 event—though this is a “must” meeting for me—I would like to share my thoughts on how that question was answered during the conference.